Beta-blocker use and breast cancer outcomes: a meta-analysis
Breast Cancer Research and Treatment · 2024-08 · 206 (3) · 443-463
DOI: 10.1007/s10549-024-07263-4 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 05.06.2024. Verfasst von Oliver William Scott und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Building 507, 85 Park Road, Grafton, Auckland, 102…. Hauptthemen laut MEDLINE: Breast Neoplasms, Adrenergic beta-Antagonists. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Auckland Medical Research Foundation.
Abstract (Originalsprache)
Purpose
Beta blockers (BBs) are commonly used cardiovascular medications, and their association with breast cancer outcomes has been examined in several previous observational studies and meta-analyses. In this study, an updated meta-analysis was undertaken to ascertain the association between BBs and both breast cancer death (BCD) and breast cancer recurrence (BCR).
Methods
Articles were sourced from various databases up until the 14th of August 2023. Effect estimates were pooled using the random effects model, and the Higgins I 2 statistic was computed to ascertain heterogeneity. Subgroup analyses were conducted by the potential for immortal time bias (ITB), the exposure period (prediagnosis vs postdiagnosis), and type of BB (selective vs non-selective). Publication bias was assessed using funnel plots and Egger’s regression tests.
Results
Twenty-four studies were included. Pooled results showed that there was no statistically significant association between BB use and both BCD (19 studies, hazard ratio = 0.90, 95% CI 0.78–1.04) and BCR (16 studies, HR = 0.87, 95% CI 0.71–1.08). After removing studies with ITB, the associations were attenuated towards the null. There was no effect modification for either outcome when stratifying by the exposure period or type of BB. There was clear evidence of publication bias for both outcomes.
Conclusion
In this meta-analysis, we found no evidence of an association between BB use and both BCD and BCR. Removing studies with ITB attenuated the associations towards the null, but there was no effect modification by the exposure period or type of BB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Building 507, 85 Park Road, Grafton, Auckland, 1023, New Zealand. o.scott@auckland.ac.nz.
- Department of Epidemiology and Biostatistics, School of Population Health, University of Auckland, Building 507, 85 Park Road, Grafton, Auckland, 1023, New Zealand.
Förderung
- Auckland Medical Research Foundation
Zitieren
APA
Scott, O. W., TinTin, S., Cavadino, A., & Elwood, J. M. (2024). Beta-blocker use and breast cancer outcomes: a meta-analysis. Breast Cancer Research and Treatment, 206(3), 443-463. https://doi.org/10.1007/s10549-024-07263-4
Vancouver
Scott OW, TinTin S, Cavadino A, Elwood JM. Beta-blocker use and breast cancer outcomes: a meta-analysis. Breast Cancer Research and Treatment. 2024;206(3):443-463. doi:10.1007/s10549-024-07263-4
BibTeX
@article{Scott2024,
author = {Scott, Oliver William and TinTin, Sandar and Cavadino, Alana and Elwood, J Mark},
title = {Beta-blocker use and breast cancer outcomes: a meta-analysis},
journal = {Breast Cancer Research and Treatment},
year = {2024},
volume = {206},
number = {3},
pages = {443--463},
doi = {10.1007/s10549-024-07263-4}
}
EUVIMED